Immunis Inc.

About Immunis Inc.

Immunis is a clinical-stage biotech company focused on developing multi-active biologics with immune modulating factors to address age-related diseases and immune dysregulation, particularly targeting muscle atrophy (sarcopenia), obesity, and reduced physical function. Their mission is to enhance immune health and muscle function to promote a healthier lifespan.

Products & Services

IMM01-STEM Therapy:An investigational therapy containing all-natural bioactive molecules aimed at improving muscle mass and strength, enhancing immune cell recruitment, increasing lean mass, reducing fat mass, and increasing physical activity in individuals with sarcopenia and knee osteoarthritis.

STEM-MYO Program:A program focused on addressing muscle atrophy, currently under clinical investigation.

STEM-META Program:A program targeting metabolic health issues, also in clinical trial phases.

Specialties

Immune Modulation Age-Related Disease Treatment Muscle Atrophy (Sarcopenia) Metabolic Health Clinical-Stage Biologics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A-1 T: - FT: Series A-1	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2025-01-11 FD: 2025-01-11	6 investors

Series A-1 Latest

2025-01-11

$25.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Hans S. Keirstead, Ph.D.

Chairman of the Board

J

Joelle Hafen

Director of Operations

T

Tom Lane, Ph.D.

Chief Science Officer

A

Abbey Abrecht

Quality Assurance Manager

P

Peter Diamandis, M.D.

Executive Advisory Board Member

M

Mark Cabato, CFA

Chief Business Officer

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Immunis Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised